Why Crossbow
We aim to cure cancer. Our team is urgently working to create an arsenal of therapeutics that expands the reach and impact of antibodies used to treat cancer.
We chose the name Crossbow because our next-generation therapies embody the precision and power of a crossbow. With unparalleled accuracy and potency, our T-Bolt™ molecules strike tumor cells like a crossbow shoots bolts at its target.
Join us on our bold quest to broaden the benefits of immunotherapy and improve the lives of people living with cancer.
What we do
Selecting from the expanding universe of cancer antigens
We identify, validate and prioritize the most promising cancer antigens for our T-Cell Receptor mimetic (TCRm) discovery efforts.
Who we are
A team of international, collaborative and experienced inventors, drug developers and company builders. We value scientific excellence, passion, integrity, innovation, transparency, respect and accountability. We embrace problems deemed impossible to solve.
Briggs Morrison,
M.D.
Chief Executive Officer, President
Michael
Princiotta, Ph.D.
Senior Vice President, Head of Biology
Benjamin Lee,
M.D., Ph.D.
Senior Vice President, Head of Translational Medicine
Dmitri
Wiederschain, Ph.D.
Chief Scientific Officer
Amanda Mak,
Ph.D.
Vice President, Head of Antibody Discovery, Protein Engineering, Process Development
Alexander Nolte,
C.P.A.
Senior Vice President, Head of Finance
Geraldine Paulus, Ph.D.
Co-founder, Vice President, Head of Corporate Development and Operations
Tao Wang,
M.S.
Vice President, Head of Product Discovery, Boston Site Head
Jeanette
Kohlbrenner, M.B.A.
Consulting Head of Human Resources
.png){kind=small}
_edited_edited.png)
_edited_edited.jpg)
_edited.jpg)
Join us
Working at Crossbow
Our people are the key to everything we accomplish. We offer outstanding programs to support your career and personal life.
Hit your next career target at Crossbow!
-
Senior Scientist/Principal Scientist, Biology – Learn more
News & Media
Keep up to date with everything happening at Crossbow.
March 5, 2024
Crossbow Therapeutics Selects First Development Candidate from its Portfolio of Next-Generation T-cell Engagers Directed at Intracellular Cancer Targets
October 11, 2023
Crossbow Therapeutics Announces Formation of its Scientific Advisory Board
July 11, 2023
Crossbow Therapeutics Launches with $80 Million in Series A Financing to Advance
a Novel Class of Antibody Therapies That Mimic T-Cell Receptors to Treat Cancer
